Sign up
Pharma Capital

Aequus Pharmaceuticals poised for increased growth with new life changing products

Aequus Pharmaceuticals (CVE:AQS) CEO Doug Janzen joined Steve Darling in the Vancouver Proactive studio to give details about his company. Those detail include drugs already at market and others in the pipeline.

Janzen also shared information on one of those drugs, Aequus 1303 which is being developed to help pregnant women with nausea. Janzen also talked about their revenue streams and future outlook for the company. 

 

View full AQS profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.